RHBDF1

Across TCGA pan-cancer cohorts, RHBDF1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated RHBDF1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RHBDF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RHBDF1 expression acts as an unfavorable survival marker.

CESC, SKCM, and ACC are the cancer types where RHBDF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	30	view →
SKCM	OS	Median	III,IV	0.254	0.737	<.001	14	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
LGG	DFS	Median	All	0.192	0.828	<.001	8	view →
LUAD	OS	Median	All	0.274	0.834	.009	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	OS	Median	III,IV	0.181	0.579	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RHBDF1–CESC (OS)

Open the CESC breakdown →